Arrowhead Buys Roche RNA Drug Assets, Doubles Burn Rate with Addition of Madison Site | GenomeWeb

By Doug Macron

Arrowhead Research this week announced that it has acquired the RNA therapeutics assets of Roche, including its 40-person operations in Madison, Wisc., in a deal that included no cash upfront but a nearly 10 percent equity stake in Arrowhead and million-dollar late-stage milestones.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.